

## **Coalesix releases next generation of its Candidate Design Environment -- Mobius 2.0**

CAMBRIDGE, MA – **November 17, 2005** – Coalesix, Inc. [www.coalesix.com](http://www.coalesix.com) today announced the release of MOBIUS 2.0, the next generation of its Candidate Design Environment (CDE).

### **mobius**

Representing another step in Coalesix's mission to improve the efficiency of drug discovery, Mobius 2.0 CDE features and capabilities include: a novel chemical editor, interactive data visualization, an enhanced structure fragment viewer, data export functionality, user interaction with *in silico* models to dynamically define target values, annotation of structures and experiments, and a history tree reflecting the sequence and relative timelines of experiments -- all of which ensure that this pioneering CDE can be utilized by research groups of all sizes and varying skill levels.

The newest release of Mobius was unveiled to strong positive reception at the eCheminfo conference and the ACS ProSpectives – Structure-Based Drug Discovery conference, both held in Philadelphia in October. In addition, Jim Wikel, Coalesix CTO, spoke on the MOBIUS technology and presented Case Studies at the eCheminfo conference.

In its latest version, research groups of all sizes can operate Mobius 2.0 CDE.

“Our new release has a flexible multi-tier architecture that supports all major operating systems and database platforms,” said Christopher Bingham, VP of Software Engineering at Coalesix. “MOBIUS can be installed on a single PC running either Windows or LINUX, or it can attach to multi-server systems and support large organizations.”

Additionally, “the new version comes with a powerful Fragment Library Editor which enables the user to construct a compound search space through nested Markush representation,” says Dr. Ihsan Ecemis, Coalesix VP of Technology “It's very intuitive and more comparable to a chemist's line of thinking.”

Mobius 2.0 CDE is a collaborative and interactive desktop-based environment that uses input from existing predictive models, human expertise and proprietary multi-parameter search algorithms to design numerous Lead series and identify alternatives for synthesis that satisfy multiple objectives.

The Mobius 2.0 CDE leverages both computational and medicinal chemistry resources in order to deliver more alternative solutions. Human expertise and predictive technology are combined through the use of its proprietary Multi-Criteria Optimization technology resulting in a potential increase in the number of candidates discovered.

Also helping to ensure Mobius 2.0 CDE can be utilized in any research effort is a new component -- known as a chemical editor -- that allows researchers to define their own search space during the lead optimization/lead generation phases. Thus, users of all computer skill-levels can work within the Mobius 2.0 environment.

“We have developed a novel optimization technology focused on providing an in silico environment that enables the identification of a diverse selection of preclinical drug candidate molecules with better overall properties,” says Jim Wikel, Coalesix Chief Technology Officer. “Consequently, Mobius 2.0 CDE supports better decision making and provides a higher likelihood of clinical success.”

Wikel concludes, “Mobius 2.0 CDE provides an intuitive interface, enables all users to quickly realize the benefits of multi-parameter optimization for lead identification and optimization.”

#### About Coalesix

Headquartered in Cambridge, MA Coalesix focuses on the development and commercialization of technology to improve the efficiency of drug discovery through the use of its Mobius Candidate Design Environment (CDE). Mobius offers drug discovery organizations the ability to maximize the return on all of their Lead Optimization/Lead Generation efforts and resources while at the same time helping overcome the lead-to-candidate bottleneck. Mobius fosters interactions between computational and medicinal chemistry to produce a novel approach to address the challenges of Lead Optimization/Lead Generation in order to enable faster identification of more potential drug candidates.

More information on Mobius and Coalesix can be obtained by contacting Bill Hayden, SVP, at: (514) 895 2455.